Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
(Continued)<br />
Mens 2007 KEN<br />
(146 participants)<br />
Ratcliff 2005 IDN<br />
(774 participants)<br />
Yeka 2007 UGA<br />
(414 participants)<br />
Zongo 2007 BFA<br />
(375 participants)<br />
verse event monitoring not described.<br />
Adverse events were recorded<br />
at each visit in the case record<br />
<strong>for</strong>m (days 0, 1, 2, 3, 7, 14, and<br />
28). An adverse event defined<br />
as any unfavourable and unintended<br />
sign.<br />
Assessed daily until fever and<br />
parasites cleared then weekly<br />
until day 42. A symptom questionnaire<br />
and physical exam at<br />
each visit. Haemoglobin was<br />
checked at each visit.<br />
Standardized history, physical<br />
exam, and malaria film on days<br />
0, 1, 2, 3, 7, 14, 21, 28, 35, and<br />
42 and any other day they were<br />
unwell<br />
Assessed at each visit including<br />
neurological examination. Adverse<br />
events described as any<br />
untoward medical occurrence.<br />
Assessed daily until day 3<br />
then weekly until day 42.<br />
A standardized history and<br />
physical exam at each visit.<br />
Haemoglobin was checked at<br />
baseline and last day of follow<br />
up.<br />
<strong>Artemisinin</strong>-<strong>based</strong> <strong>combination</strong> <strong>therapy</strong> <strong>for</strong> treating uncomplicated malaria (Review)<br />
Copyright © 2009 <strong>The</strong> <strong>Cochrane</strong> Collaboration. Published by John Wiley & Sons, Ltd.<br />
study drug<br />
No other significant differences are noted between<br />
treatments<br />
Open label SAE: 1 patient treated with DHA-P died on day<br />
14. Assessed as unrelated to treatment.<br />
GI: No difference in anorexia, abdominal pain,<br />
diarrhoea, or vomiting<br />
CVS/RS: No difference in cough<br />
CNS: Weakness more common with AL6 (P =<br />
0.035). No difference in headache.<br />
Derm: No difference in pruritis<br />
Open label SAE: 1 death 60 days after treatment. Cause not<br />
known<br />
GI: Diarrhoea was more common with DHA-P<br />
(P = 0.003). Nausea, vomiting, abdominal pain,<br />
and anorexia not different<br />
CNS: Headache and dizziness not significantly<br />
different<br />
CVS/RS: Palpitations and cough not different<br />
Other: No difference in rash or myalgia<br />
Single Blind SAE: 2 with AL, 5 with DHA-P, all judged unrelated<br />
to study meds (2 convulsions, 2 pyomyositis,<br />
vomiting, severe anaemia, dehydration)<br />
GI: Abdominal pain more common with AL (P<br />
= 0.05). No difference in anorexia, vomiting or<br />
diarrhoea.<br />
RS/CVS: No difference in cough or coryza<br />
CNS: No difference in malaise/weakness<br />
Derm: No difference in pruritis<br />
Overall comment: Most AE were of mild to moderate<br />
severity and consistent with symptoms of<br />
malaria<br />
Open label SAE: None observed<br />
GI: Less abdominal pain with DHA-P (P < 0.05),<br />
vomiting, diarrhoea, and anorexia not different<br />
CNS: Less headache with DHA-P (P < 0.05), no<br />
difference in weakness<br />
CVS/RS: No difference in cough<br />
222